A large, multi-institutional study demonstrates that a blood test to detect circulating tumor DNA can accurately predict recurrence of HPV-driven oropharyngeal cancer following treatment. Results also indicate that the biomarker test may detect recurrent disease earlier than imaging or other standard methods of post-treatment surveillance, allowing physicians to personalize treatment more quickly for patients whose cancer returns. Findings from the study will be presented today at the 2022 Multidisciplinary Head and Neck Cancers Symposium.

Roughly 15-25% of patients with HPV-driven oropharyngeal cancer experience recurrence after treatment, often presenting as distant disease that has spread past the throat and neck. Currently, recurrence is detected primarily through imaging and physical exams, but there is wide variability in the use and frequency of these surveillance methods.

"While detection of tumor-specific DNA circulating in a patient's bloodstream has shown potential as a powerful yet minimally invasive diagnostic tool for several cancers, this is the first study to demonstrate broad clinical utility and validity of the biomarker in HPV-driven oropharyngeal cancer," said presenting author Glenn J. Hanna, MD, Director of the Center for Salivary and Rare Head and Neck Cancers at the Dana-Farber Cancer Institute.

In the study, researchers retrospectively examined data from 1,076 patients who had one or more tests to detect circulating tumor tissue modified viral (TTMV)-HPV DNA as part of their post-treatment surveillance. All patients were examined more than three months after completing standard treatment with surgery, radiation therapy and/or chemotherapy.

Of the 80 patients (7% of the total sample) who tested positive for the biomarker in surveillance, 95% were confirmed through imaging, biopsy and/or endoscopy as having recurrent HPV-positive disease. The presence of TTMV-HPV DNA was the first indicator of recurrence for 72% of the patients whose cancer returned, and roughly half of the recurrences (48%) were found in patients tested more than 12 months after completing therapy.

"Most patients had no other evidence of disease or clinically indeterminate disease status at the time of their first positive biomarker test," said Dr. Hanna. "Incorporating a test for TTMV-HPV DNA into routine post-treatment follow-up can enable physicians to detect recurrent cancers earlier and allow us to start recommended interventions more quickly to improve outcomes."

###

Dr. Hanna will present this study in Plenary Session I on Thursday, February 24, at 1:50 p.m. Mountain time.  To access the meeting or schedule interviews with researchers, contact ASTRO's media relations team at press@astro.org. The abstract is available online.

This study was supported by Naveris. Disclosures for Dr. Hanna are available online.

This release contains updated study information from the author.

Attribution to the 2022 Multidisciplinary Head & Neck Cancers Symposium requested in all coverage.

Resources for Patients and Caregivers

• Videos: Radiation Therapy for Head and Neck Cancers; (Spanish version), An Introduction to Radiation Therapy; (Spanish version)
• Digital brochure: Radiation Therapy for Head and Neck Cancers
• ASTRO's clinical guidelines
• Additional patient brochures, videos and information on radiation therapy from RTAnswers.org

About the Symposium
The 2022 Multidisciplinary Head and Neck Cancers Symposium takes place February 24-26 at the JW Marriott Phoenix Desert Ridge in Phoenix, Arizona. This two-and-a-half-day meeting for the head and neck cancer community provides up-to-date information on clinical research, treatment strategies, supportive care, scientific breakthroughs and toxicity mitigation for patients with head and neck cancers. A major focus is placed on the multidisciplinary nature of disease management and the incorporation of all treatment modalities to achieve best outcomes. The meeting is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the American Head & Neck Society (AHNS) and the Society for Immunotherapy of Cancer (SITC).

About ASTRO
The American Society for Radiation Oncology (ASTRO) is the largest radiation oncology society in the world, with nearly 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. For information on radiation therapy, visit RTAnswers.org. To learn more about ASTRO, visit our website and follow us on social media.